{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T20:31:09Z","timestamp":1792528269856,"version":"4.5.0"},"reference-count":33,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Objective: To evaluate the impact of recommendations issued by the Pharmacovigilance Risk Assessment Committee (PRAC) and endorsed by the European Medicines Agency (EMA) and the Italian Medicines Agency (AIFA) on rheumatologists\u2019 prescribing patterns of Janus kinase inhibitors (JAK inhibitors) and biologic disease-modifying antirheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA), within a personalized, risk-adapted care framework. Methods: A brief survey was conducted across 21 Italian rheumatology centers. This retrospective multicenter study included 4421 RA patients assessed before PRAC recommendations (1 January 2022\u20131 January 2023) and 4376 patients evaluated afterward (2 January 2023\u20131 January 2024). Prescribing behaviors, cardiovascular risk management, and clinical outcomes were compared between cohorts. Results: Following PRAC recommendations, a more individualized cardiovascular risk management strategy was observed, with increased use of targeted treatments for hypercholesterolemia, hypertension, and diabetes. The post-PRAC cohort showed a significant reduction in myocardial infarction incidence (0.90% vs. 0.47%; p = 0.02) and increased statin use (8.25% vs. 11.1%; p = 0.05). No increase in cardiovascular risk was observed among JAK inhibitor users. Notably, upadacitinib utilization remained stable despite regulatory restrictions. Conclusions: PRAC recommendations promoted safer prescribing practices and improved cardiovascular risk stratification in RA. These findings support a shift toward precision medicine, integrating real-world evidence with advanced diagnostic and decision-support tools, including future artificial intelligence-based approaches, to optimize personalized therapeutic strategies in autoimmune diseases.<\/jats:p>","DOI":"10.3390\/jpm16020107","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T11:16:38Z","timestamp":1770722198000},"page":"107","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Impact of PRAC EMA\/AIFA Recommendations on the Prescriptions of JAKi and b-DMARDs: Preliminary Results of the Survey from 21 Rheumatological Italian Centers Affiliated with CReI"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5009-1161","authenticated-orcid":false,"given":"Emanuele Antonio Maria","family":"Cassar\u00e0","sequence":"first","affiliation":[{"name":"Rheumatology Unit, Hospital S. Giovanni di Dio, Via di Torregalli n\u00b0 3, 50143 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3255-3307","authenticated-orcid":false,"given":"Daniela","family":"Marotto","sequence":"additional","affiliation":[{"name":"Rheumatology Service, ASL Gallura, 07026 Olbia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crescenzio","family":"Bentivenga","sequence":"additional","affiliation":[{"name":"Internal Medicine Unit, S. Orsola Malpighi Polyclinic, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis-Severino","family":"Martin Martin","sequence":"additional","affiliation":[{"name":"Internal Medicine Hospital, Velletri, 00045 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianpiero","family":"Baldi","sequence":"additional","affiliation":[{"name":"Rheumatology Clinic, ASL 4, 00053 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norma","family":"Carrozzo","sequence":"additional","affiliation":[{"name":"Rheumatology Clinic, 72100 Brindisi, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Zicolella","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Santo Spirito Hospital, 65124 Pescara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9342-2445","authenticated-orcid":false,"given":"Riccardo","family":"Terenzi","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Hospital S. Giovanni di Dio, Via di Torregalli n\u00b0 3, 50143 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7379-4732","authenticated-orcid":false,"given":"Andrea","family":"Delle Sedie","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8180-6660","authenticated-orcid":false,"given":"Maurizio","family":"Benucci","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Hospital S. Giovanni di Dio, Via di Torregalli n\u00b0 3, 50143 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and Management of Rheumatoid Arthritis: A Review","volume":"320","author":"Aletaha","year":"2018","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"Traves","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1002\/art.34329","article-title":"The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-and interleukin-17 production by human CD4+ T cells","volume":"64","author":"Maeshima","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41584-022-00767-7","article-title":"Oral surveillance and JAK inhibitor safety: The theory of relativity","volume":"18","author":"Winthrop","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/acr2.11232","article-title":"Postapproval Comparative Safety Study of Tofacitinib and Biological Disease-Modifying Antirheumatic Drugs: 5-Year Results from a United States\u2013Based Rheumatoid Arthritis Registry","volume":"3","author":"Kremer","year":"2021","journal-title":"ACR Open Rheumatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13075-019-1866-2","article-title":"Safety and efficacy of tofacitinib for up to 9.5years in the treatment of rheumatoid arthritis: Final results of a global, open-label, long-term extension study","volume":"21","author":"Wollenhaupt","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/jcpt.13142","article-title":"Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis","volume":"45","author":"Lee","year":"2020","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/rheumatology\/kead448","article-title":"Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases","volume":"63","author":"Taylor","year":"2024","journal-title":"Rheumatol"},{"key":"ref_13","unstructured":"European Medicines Agency (EMA) (2026, January 01). Pharmacovigilance Risk Assessment Committee (PRAC). Available online: https:\/\/www.ema.europa.eu\/en\/committees\/pharmacovigilance-risk-assessment-committee-prac."},{"key":"ref_14","unstructured":"European Medicines Agency (2026, January 01). EMA Confirms Measures to Minimize Risk of Serious Side Effects with Janus Kinase Inhibitors for Chronic Inflammatory Disorders. Available online: https:\/\/www.ema.europa.eu\/en\/news\/ema-confirms-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic-inflammatory-disorders."},{"key":"ref_15","unstructured":"SCORE2 Working Group, and ESC Cardiovascular Risk Collaboration (2021). SCORE2 risk prediction algorithms: New models to estimate 10-year risk of cardiovascular disease in Europe. Eur. Heart J., 42, 2439\u20132454."},{"key":"ref_16","first-page":"1784","article-title":"Italian recommendations for the assessment of cardiovascular risk in rheumatoid arthritis: A position paper of the Cardiovascular Obesity and Rheumatic DISease (CORDIS) Study Group of the Italian Society for Rheumatology","volume":"41","author":"Cacciapaglia","year":"2023","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Strunz, P.P., Risser, L.M., Englbrecht, M., Witte, T., Froehlich, M., Schmalzing, M., Gernert, M., Hueper, S., Bartz-Bazzanella, P., and von der Decken, C. (2024). Use of Janus kinase inhibitors before and after European Medicines Agency safety recommendations: A retrospective study. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1445680"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/acr2.11602","article-title":"Changes in patterns of use of advanced therapies following emerging data about adverse events in patients with rheumatoid arthritis from the Veterans Affairs Health System","volume":"5","author":"Jeong","year":"2023","journal-title":"ACR Open Rheumatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s00296-025-05859-7","article-title":"Janus kinase inhibitors show a longer drug survival than biologics in a real-world cohort of patients with rheumatoid arthritis\u2014A retrospective analysis from the RHADAR database","volume":"45","author":"Risser","year":"2025","journal-title":"Rheumatol. Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/acr.25268","article-title":"Changes in Characteristics of Patients Initiating and Discontinuing Advanced Therapies for Rheumatoid Arthritis Following the Release of Safety Data","volume":"76","author":"Song","year":"2024","journal-title":"Arthritis Care Res."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Philippoteaux, C., Deprez, V., Nottez, A., Cailliau, E., Houvenagel, E., Deprez, X., Philippe, P., Pascart, T., Flipo, R.M., and Go\u00ebb, V. (2022). Characteristics of Patients Treated with JAK Inhibitors in Rheumatoid Arthritis before versus after VTE Risk Warnings. J. Clin. Med., 12.","DOI":"10.3390\/jcm12010207"},{"key":"ref_22","first-page":"393","article-title":"Evaluation of the global cardiovascular absolute risk: The Progetto CUORE individual score","volume":"40","author":"Palmieri","year":"2004","journal-title":"Ann. Ist. Super. Sanita"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update","volume":"76","author":"Agca","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1093\/rheumatology\/keaf096","article-title":"Comparative safety of biologic and targeted synthetic disease-modifying anti-rheumatic drugs for cardiovascular outcomes in rheumatoid arthritis","volume":"64","author":"Sendaydiego","year":"2025","journal-title":"Rheumatology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e2531204","DOI":"10.1001\/jamanetworkopen.2025.31204","article-title":"Comparative Safety of JAK Inhibitors vs TNF Antagonists in Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis","volume":"8","author":"Solitano","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ard.2025.08.028","article-title":"Use of statins and its association with major adverse cardiovascular events with tofacitinib vs TNF inhibitors in patients with rheumatoid arthritis with and without atherosclerotic cardiovascular disease","volume":"85","author":"Giles","year":"2025","journal-title":"Ann. Rheum. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e005371","DOI":"10.1136\/rmdopen-2024-005371","article-title":"Benefit-risk analysis of upadacitinib versus adalimumab in patients with rheumatoid arthritis and higher or lower risk of cardiovascular disease","volume":"11","author":"Burmester","year":"2025","journal-title":"RMD Open"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Makris, A., Barkas, F., Sfikakis, P.P., Liberopoulos, E., and Agouridis, A.P. (2022). The Effect of Upadacitinib on Lipid Profile and Cardiovascular Events: A Meta-Analysis of Randomized Controlled Trials. J. Clin. Med., 11.","DOI":"10.3390\/jcm11236894"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1002\/art.39195","article-title":"Derivation and internal validation of an expanded cardiovascular risk prediction score for rheumatoid arthritis: A Consortium of Rheumatology Researchers of North America Registry Study","volume":"67","author":"Solomon","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Favalli, E.G., Cincinelli, G., Germinario, S., Di Taranto, R., Orsini, F., Maioli, G., Biggioggero, M., Ferrito, M., and Caporali, R. (2023). The impact of EMA recommendations on the real-life use of Janus kinases inhibitors for rheumatoid arthritis: The Expanded Risk Score in RA as a tool to quantify the risk of cardiovascular events. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1225160"},{"key":"ref_31","unstructured":"Raschella, M., Furia, G., Di Nunzio, M., Renzullo, F.L., Girelli, F., Pignatti, F., Ursini, F., Vultaggio, L., Cataleta, P., and Bravi, E. (2025, January 26\u201329). Clinical impact of therapeutic variation in relation to the modification of the AIFA remorseability criteria for Jak inhibitors in patients with RA, in remission or low disease activity: Analysis of the multicenter JAK-SWAP RER study in Emilia Romagna. Proceedings of the 62th Conference of the Italian Society for Rheumatology, Rimini, Italy."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"105592","DOI":"10.1016\/j.jbspin.2023.105592","article-title":"Recommendations for assessing the risk of cardiovascular disease and venous thromboembolism before the initiation of targeted therapies for chronic inflammatory rheumatic diseases","volume":"90","author":"Avouac","year":"2023","journal-title":"Jt. Bone Spine"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Benucci, M., Bardelli, M., Cazzato, M., Bartoli, F., Damiani, A., Li Gobbi, F., Bandinelli, F., Panaccione, A., Di Cato, L., and Niccoli, L. (2024). Efficacy and Safety of Filgotinib in Rheumatoid Arthritis Patients Aged over and under 65 Years (ENANTIA-65). J. Pers. Med., 14.","DOI":"10.3390\/jpm14070712"}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/16\/2\/107\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T11:39:43Z","timestamp":1770723583000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/16\/2\/107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["jpm16020107"],"URL":"https:\/\/doi.org\/10.3390\/jpm16020107","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]}}}